S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Corcept Therapeutics (CORT) Stock Forecast, Price & News

+0.51 (+2.68%)
(As of 05/17/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
565,844 shs
Average Volume
946,008 shs
Market Capitalization
$2.08 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Corcept Therapeutics logo

About Corcept Therapeutics

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.


Corcept Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$365.98 million
Cash Flow
$1.03 per share
Book Value
$3.26 per share


Net Income
$112.51 million
Pretax Margin




Free Float
Market Cap
$2.08 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.55 out of 5 stars

Medical Sector

106th out of 1,426 stocks

Pharmaceutical Preparations Industry

41st out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

Is Corcept Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Corcept Therapeutics stock.
View analyst ratings for Corcept Therapeutics
or view top-rated stocks.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Corcept Therapeutics

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Thursday, May, 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.03. The biotechnology company earned $93.70 million during the quarter, compared to analysts' expectations of $103.23 million. Corcept Therapeutics had a trailing twelve-month return on equity of 24.23% and a net margin of 29.42%. The firm's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 EPS.
View Corcept Therapeutics' earnings history

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.00 million-$430.00 million, compared to the consensus revenue estimate of $413.85 million.

What price target have analysts set for CORT?

4 brokers have issued twelve-month price objectives for Corcept Therapeutics' stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate Corcept Therapeutics' share price to reach $29.67 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts' price targets for Corcept Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the following people:
  • Dr. Joseph K. Belanoff M.D., Co-Founder, Pres, CEO & Director (Age 65, Pay $1.69M)
  • Mr. Atabak Mokari, CFO & Treasurer (Age 45, Pay $687.98k)
  • Dr. Hazel Hunt Ph.D., Chief Scientific Officer
  • Mr. Sean Maduck, Pres of Corcept Endocrinology (Age 45, Pay $828.83k) (LinkedIn Profile)
  • Mr. Gary Charles Robb, Chief Bus. Officer & Sec. (Age 59, Pay $900.08k) (LinkedIn Profile)
  • Mr. Joseph Douglas Lyon, Chief Accounting Officer (Age 43) (LinkedIn Profile)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Ms. Amy Flood, Chief HR & Communications Officer
  • Donald E. Laferle, Sr. VP
  • Dr. William Guyer Pharm.D., Chief Devel. Officer
What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics CEO Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among Corcept Therapeutics' employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.52%), Vanguard Group Inc. (9.82%), Renaissance Technologies LLC (7.31%), Ingalls & Snyder LLC (6.50%), Federated Hermes Inc. (4.46%) and State Street Corp (3.21%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Vanguard Group Inc., Renaissance Technologies LLC, TD Asset Management Inc., Northern Trust Corp, Jane Street Group LLC, Martingale Asset Management L P, and Bank of New York Mellon Corp. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, Gary Charles Robb, and Sean Maduck.
View insider buying and selling activity for Corcept Therapeutics
or view top insider-selling stocks.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Great Lakes Advisors LLC, BlackRock Inc., Boston Trust Walden Corp, Hillsdale Investment Management Inc., Royce & Associates LP, Ingalls & Snyder LLC, and Parallel Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, and G Leonard Baker, Jr.
View insider buying and selling activity for Corcept Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $19.55.

How much money does Corcept Therapeutics make?

Corcept Therapeutics has a market capitalization of $2.08 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $0.909990 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

Corcept Therapeutics employs 238 workers across the globe.

When was Corcept Therapeutics founded?

Corcept Therapeutics was founded in 1998.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 327-3270, via email at [email protected], or via fax at 650-327-3218.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.